索马鲁肽口服剂：开启GLP-1受体激动剂的新时代  

Oral Semaglutide: A herald to Open the Upcoming Era of Glucagon-like Peptide-1 Receptor Oral Agonist

作　　者：李艳梅 唐祎偌 夏旋 LI Yan-mei;TANG Yi-ruo;XIA Xuan(Department of Physiology and Pathophysiology,College of Medical Sciences,China Three Gorges University,Yichang Hubei 443002,China)

机构地区：[1]三峡大学医学院生理与病理生理学系

出　　处：《药品评价》2019年第24期1-3,5,共4页Drug Evaluation

基　　金：湖北省自然科学基金面上项目(2015CFB316)资助

摘　　要：2019年9月20日,诺和诺德公司研发的索马鲁肽口服制剂(每日1次)在美国上市,这是首个上市的胰高糖素样肽-1受体激动剂(GLP-1RA)口服制剂,这大大增加2型糖尿病患者使用GLP-1RA的便捷性与依从性。本文将重点从索马鲁肽口服制剂的疗效、药物相互作用、心肝肾功能不全患者的注意事项等方面,来阐述索马鲁肽口服剂的研究进展。On September 20th 2019,Novo Nordisk announced official approval on the market of its new drug-oral tablet semaglutide,which would the first once-daily oral glucagon-like peptide-1 receptor agonist(GLP-1RA)and affiliate the convenience and compliance of patients with type 2 diabetes in clinics.This review would focus on the efficacy,drug interaction and indication for patients with heart,renal or hepatic insufficiency by oral semaglutide.

关 键 词：索马鲁肽 口服制剂 糖尿病 胰高糖素样肽1受体激动剂 

分 类 号：R977.15[医药卫生—药品]